Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute/NIH, Bethesda, MD 20892, USA.
Am J Clin Pathol. 2011 Jun;135(6):890-900. doi: 10.1309/AJCPV2D1DDSGJDBW.
Flow cytometric T-cell receptor (TCR)-V(β) repertoire analysis (TCR-V(β)-R) is a sensitive method for detection of T-cell clonality; however, no uniform approach exists to define clonality in neoplastic T cells. TCR-V(β)-R was evaluated in patients with a diagnosis of T-cell neoplasia in initial diagnostic specimens from 41 patients and for minimal residual disease (MRD) monitoring in 61 sequential samples from 14 patients with mature T-cell neoplasia. Gating strategies and criteria for detection of T-cell clonality were determined. In all 41 initial specimens, T-cell clonality was demonstrated via TCR-V(β)-R. The frequency of V(β) usage was consistent with random neoplastic transformation of TCR-V(β) subsets. MRD was successfully detected in follow-up samples from all 14 patients evaluated, Furthermore, MRD after therapy was quantitated in 48 peripheral blood specimens. TCR-V(β)-R analysis is a sensitive method for detection of T-cell clonality and is useful for diagnosis and MRD detection in multiple specimen types.
流式细胞术 T 细胞受体（TCR）-V（β）谱系分析（TCR-V（β）-R）是检测 T 细胞克隆性的敏感方法；然而，目前尚不存在用于定义肿瘤性 T 细胞克隆性的统一方法。我们在 41 例 T 细胞肿瘤诊断初始标本中评估了 TCR-V（β）-R，并在 14 例成熟 T 细胞肿瘤患者的 61 个连续样本中进行了微小残留病（MRD）监测。确定了门控策略和检测 T 细胞克隆性的标准。在所有 41 例初始标本中，均通过 TCR-V（β）-R 显示 T 细胞克隆性。V（β）的使用频率与 TCR-V（β）亚群的随机肿瘤转化一致。对评估的 14 例患者的所有随访样本均成功检测到 MRD，此外，还对 48 份外周血样本进行了治疗后的 TCR-V（β）-R 分析。TCR-V（β）-R 分析是一种检测 T 细胞克隆性的敏感方法，可用于多种标本类型的诊断和 MRD 检测。
